MacroGenics, Inc. (MGNX): Price and Financial Metrics

MacroGenics, Inc. (MGNX): $3.34

0.01 (+0.30%)

POWR Rating

Component Grades













Add MGNX to Watchlist
Sign Up

Industry: Biotech



in industry


  • MGNX scores best on the Value dimension, with a Value rank ahead of 61.02% of US stocks.
  • The strongest trend for MGNX is in Stability, which has been heading up over the past 179 days.
  • MGNX ranks lowest in Momentum; there it ranks in the 4th percentile.

MGNX Stock Summary

  • Of note is the ratio of Macrogenics Inc's sales and general administrative expense to its total operating expenses; merely 9.64% of US stocks have a lower such ratio.
  • As for revenue growth, note that MGNX's revenue has grown -26.16% over the past 12 months; that beats the revenue growth of only 6.14% of US companies in our set.
  • In terms of volatility of its share price, MGNX is more volatile than 87.72% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Macrogenics Inc, a group of peers worth examining would be IMGN, CLLS, ABUS, LPTX, and ATHX.
  • Visit MGNX's SEC page to see the company's official filings. To visit the company's web site, go to

MGNX Valuation Summary

  • MGNX's EV/EBIT ratio is -9.9; this is 133.79% lower than that of the median Healthcare stock.
  • MGNX's EV/EBIT ratio has moved up 169 over the prior 96 months.
  • Over the past 96 months, MGNX's EV/EBIT ratio has gone up 169.

Below are key valuation metrics over time for MGNX.

Stock Date P/S P/B P/E EV/EBIT
MGNX 2021-08-31 12.2 4.5 -11.2 -9.9
MGNX 2021-08-30 12.0 4.5 -11.0 -9.8
MGNX 2021-08-27 12.2 4.5 -11.2 -9.9
MGNX 2021-08-26 11.7 4.4 -10.7 -9.5
MGNX 2021-08-25 11.6 4.3 -10.7 -9.4
MGNX 2021-08-24 12.0 4.5 -11.0 -9.8

MGNX Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 34.78%.
  • The 5 year cash and equivalents growth rate now stands at -38.76%.
  • Its 5 year price growth rate is now at -60.95%.
MGNX's revenue has moved up $45,026,000 over the prior 70 months.

The table below shows MGNX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 77.447 -143.83 -202.115
2021-09-30 115.991 -95.054 -146.18
2021-06-30 118.582 -105.936 -129.337
2021-03-31 108.082 -96.792 -136.287
2020-12-31 104.883 -111.898 -129.739
2020-09-30 77.384 -144.409 -158.048

MGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MGNX has a Quality Grade of C, ranking ahead of 36.14% of graded US stocks.
  • MGNX's asset turnover comes in at 0.284 -- ranking 156th of 681 Pharmaceutical Products stocks.
  • SRNE, CNCE, and VBLT are the stocks whose asset turnover ratios are most correlated with MGNX.

The table below shows MGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.284 0.985 -0.809
2021-06-30 0.294 1.000 -0.724
2021-03-31 0.285 1.000 -0.860
2020-12-31 0.312 1.000 -0.859
2020-09-30 0.242 1.000 -1.055
2020-06-30 0.248 1.000 -1.081

MGNX Price Target

For more insight on analysts targets of MGNX, see our MGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.25 Average Broker Recommendation 1.45 (Moderate Buy)

MGNX Stock Price Chart Interactive Chart >

Price chart for MGNX

MGNX Price/Volume Stats

Current price $3.34 52-week high $29.16
Prev. close $3.33 52-week low $2.13
Day low $3.08 Volume 2,504,900
Day high $3.35 Avg. volume 900,716
50-day MA $4.80 Dividend yield N/A
200-day MA $12.81 Market Cap 204.85M

MacroGenics, Inc. (MGNX) Company Bio

Macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company was founded in 2000 and is based in Rockville, Maryland.

MGNX Latest News Stream

Event/Time News Detail
Loading, please wait...

MGNX Latest Social Stream

Loading social stream, please wait...

View Full MGNX Social Stream

Latest MGNX News From Around the Web

Below are the latest news stories about Macrogenics Inc that investors may wish to consider to help them evaluate MGNX as an investment opportunity.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2022: Cowen 42nd Annual Health Care Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Ge

Yahoo | March 3, 2022

What 4 Analyst Ratings Have To Say About Macrogenics

Analysts have provided the following ratings for Macrogenics (NASDAQ: MGNX ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Macrogenics. The company has an average price target of $28.75 with a high of $40.00 and a low of $21.00. Below is a summary of how these 4 analysts rated Macrogenics over the past 3 months. The greater the number of bullish ratings, … Full story available on

Benzinga | February 28, 2022

MacroGenics upgraded to buy at Citi on valuation

Citi has upgraded MacroGenics (MGNX) to buy from neutral saying the company''s pipeline has "entered undervalued territory."

Seeking Alpha | February 28, 2022

MacroGenics Announces Executive Promotion

ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer, as of February 22. Mr. Risser joined MacroGenics in 2009 and has played an instrumental leadership role in sourcing, structuring and negotiating the company's collaboration partnerships and has been res

Yahoo | February 28, 2022

MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials

No summary available.

Seeking Alpha | February 25, 2022

Read More 'MGNX' Stories Here

MGNX Price Returns

1-mo -4.57%
3-mo -60.38%
6-mo -79.46%
1-year -87.71%
3-year -79.94%
5-year -81.06%
YTD -79.19%
2021 -29.79%
2020 110.11%
2019 -14.33%
2018 -33.16%
2017 -7.05%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.596 seconds.